Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was and whether it warranted making the drug available for patients facing a fatal disease with few other options.
1don MSN
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.
Stock index futures in the United States are experiencing a slight pullback this morning, following a two-day rally that interrupted a ...
Investor's Business Daily on MSN20h
Sarepta's 20% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.
Health-care companies' shares were flat as traders rotated into sectors that are less sensitive to shifts in interest-rate expectations. The Health and Human Services Department is weighing plans to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback